Trial · NCT07120750
Post-Radical Treatment Antiviral Strategies in HBV-Related Liver Cancer: Impact on Tumor Prognosis
NCT07120750, Not yet recruiting, Shenzhen Third People's Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Post-Radical Treatment Antiviral Strategies in HBV-Related Liver Cancer: Impact on Tumor Prognosis. Trials, record NCT07120750. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07120750
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Post-Radical Treatment Antiviral Strategies in HBV-Related Liver Cancer: Impact on Tumor Prognosis
- NCT number
- NCT07120750
- Status
- Not yet recruiting
- Enrollment
- 332 participants, estimated
- Lead sponsor
- Shenzhen Third People's Hospital
- Conditions
- Hepatocellular Carcinoma (HCC), Chronic Hepatitis B
- Interventions
- Intervention for Group 1, Intervention for Group 2
- First posted
- 2025-08-13
- Last updated
- 2025-08-13
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 3-Year Cumulative Recurrence Rate via MRI (LI-RADS) | 3 years post-radical treatment. | 1. Measurement Tool: Liver Imaging Reporting and Data System (LI-RADS v2018) 1.1 Primary modality: Dynamic contrast-enhanced MRI 1.2 Confirmatory criteria: 1.2.1 LI-RADS 5 (definite HCC): 1.2.1.1 Arterial hyperenhancement + 1.2.1.2 Portal venous washout ± 1.2.1.3 Capsule/threshold growth 1.2.2 Histopathology (biopsy) for equivocal cases 2. Definition: Proportion of participants with new intrahepatic lesions meeting LI-RADS 5 criteria or histologically confirmed HCC metastases within 3 years post-radical treatment. 3. Clinical Significance: Recurrence defined as: 3.1 Local (original site) 3.2 Intrahepatic (\>2 cm from resection margin) 3.3 Extrahepatic (metastases with biopsy confirmation) |
| Secondary | 2-Year HBsAg Seroclearance Rate | 2 years post-treatment initiation. | * Measurement Tool: Architect HBsAg QT Assay * Definition: Proportion with HBsAg loss (\<0.05 IU/mL) * Directionality: Lower HBsAg levels indicate better response * Confirmation: Required at two timepoints ≥24 weeks apart |
| Secondary | 2-Year HBV DNA undetectable rate | 2 years post-treatment initiation. | * Measurement Tool: COBAS® TaqMan HBV Test v2.0 * Definition: Proportion of participants achieving HBV DNA \<10 IU/mL (LLOQ) in two consecutive tests ≥6 months apart * Directionality: Lower values indicate better virological control |
| Secondary | Incidence of Adverse Events (AEs) | Throughout the 3-year follow-up period. | * Measurement Tool: CTCAE v5.0 grading system * Definition: Frequency of all-cause AEs, categorized by: * Severity: Grade 1 (mild) to 5 (death) * Relatedness: Definite/probable/possible vs. unrelated * Range: 1-5 scale (higher grade = worse severity) * Reporting Threshold: All events ≥Grade 2 |
| Secondary | Serious Adverse Event (SAE) Rate | Throughout the 3-year follow-up period. | * Measurement Tool: CTCAE v5.0 * Definition: Events meeting ≥1 SAE criterion: Death/life-threatening Hospitalization/prolonged hospitalization Persistent disability Congenital anomaly -Causality Assessment: Using WHO-UMC system |
| Secondary | Liver Function Deterioration Rate | Throughout the 3-year follow-up period. | * Measurement tool: Change in Child-Pugh score ≥ 2 points * Range: 5 - 15 points (the higher the score, the worse the liver function) * Definition: The proportion of patients with an increase in Child-Pugh score of ≥ 2 points during treatment compared to the baseline. |
| Secondary | Quality of Life Change | Throughout the 3-year follow-up period. | * Measurement tool: EORTC QLQ-C30 * Range: 0-100 (higher scores on functional dimensions indicate better status; higher scores on symptom dimensions indicate worse status) * Definition: Change from baseline in global health status/QoL over 3 years, analyzed with a mixed-effects linear model. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07120750
GET https://conductscience.org/api/trials/v1/NCT07120750/registered